1A796849-8FD9-4B27-9CD9-A17B04CBE264
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 46.02496714848883
- age_years
- 30
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.529
- TGF_BETA_SIGNALING+0.472
- MYC_TARGETS_V1+0.447
- MYC_TARGETS_V2+0.383
- OXIDATIVE_PHOSPHORYLATION+0.364
- DNA_REPAIR+0.354
- MTORC1_SIGNALING+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.349
- PROTEIN_SECRETION+0.342
- ADIPOGENESIS+0.334
Top 10 suppressed
- KRAS_SIGNALING_DN-0.171
- ANGIOGENESIS-0.161
- SPERMATOGENESIS-0.123
- MYOGENESIS-0.115
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.063
- COAGULATION-0.056
- APICAL_JUNCTION-0.033
- IL6_JAK_STAT3_SIGNALING-0.012
- IL2_STAT5_SIGNALING+0.015
- PANCREAS_BETA_CELLS+0.016
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.918 |
| 2 | 7E9D6B6D-3276-4240-B5C5-F3F982076358 | — | — | 0.905 |
| 3 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.900 |
| 4 | BE6A3670-34C4-4FD3-9794-C5B3254D9224 | — | — | 0.892 |
| 5 | EA485E4A-5956-430C-8584-E14D865E3758 | — | — | 0.884 |
| 6 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.873 |
| 7 | 5889DC37-2B83-4FA7-926E-EA69556FB769 | — | — | 0.872 |
| 8 | C969CDC5-D2DC-4F7B-B84B-C53CEF26B2CF | — | — | 0.872 |
| 9 | SRR934819 | — | — | 0.871 |
| 10 | 33060001-05C9-4751-AA58-F194207ACC08 | — | — | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.529 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.472 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.447 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.383 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.364 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.354 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.349 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.342 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.334 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.325 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.282 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.272 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.236 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.229 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| PEROXISOME | 0.217 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.209 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.197 | Inavolisib | — uncovered |